References
- Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N. Engl. J. Med.339, 1044–1053 (1998).
- Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease. Neuropathol. Appl. Neurobiol.15, 27–44 (1989).
- Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry55, 181–184 (1992).
- Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24, 197–211 (2003).
- Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol.5, 235–245 (2006).
- Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord.16, 448–458 (2001).
- Marsden CD. Problems with long-term levodopa therapy for Parkinson’s disease. Clin. Neuropharmacol.17(Suppl. 2), S32–S44 (1994).
- Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol.5, 677–687 (2006).
- Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med.342, 1484–1491 (2000).
- Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol.61, 1044–1053 (2004).
- Olanow CW, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov. Disord.19, 997–1005 (2004).
- Schapira AH, Gu M, Taanman JW et al. Mitochondria in the etiology and pathogenesis of Parkinson’s disease. Ann. Neurol.44, S89–S98 (1998).
- Parker WD, Swerdlow RH. Mitochondrial dysfunction in idiopathic Parkinson disease. Am. J.Hum. Genet.62, 758–762 (1998).
- DATATOP Study. Effect of deprenyl on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. N. Engl. J. Med.321, 1364–1371 (1989).
- LeWitt PA. Deprenyl’s effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group. Acta Neurol. Scand. Suppl.136, 79–86 (1991).
- Shults CW, Oakes D, Kieburtz K et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol.59, 1541–1550 (2002).
- Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol.54, 93–101 (2003).
- Ahlskog JE. Slowing Parkinson’s disease progression: recent dopamine agonist trials. Neurology60, 381–389 (2003).
- Morrish PK. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease. JAMA288, 312; author reply 312–313 (2002).
- Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med.351, 2498–2508 (2004).
- Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol.61, 561–566 (2004).
- Schapira AH, Obeso J. Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Ann. Neurol.59, 559–562 (2006).
- Olanow CW, Schapira AH, LeWitt PA et al. TCH346 as a neuroprotective drug in Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol.5, 1013–1020 (2006).
- Lang AE, Gill S, Patel NK et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol.59, 459–466 (2006).
- Ravina BM, Fagan SC, Hart RG et al. Neuroprotective agents for clinical trials in Parkinson’s disease: a systematic assessment. Neurology60, 1234–1240 (2003).
- Bezard E. Neuroprotection for Parkinson’s disease: a call for clinically driven experimental design. Lancet Neurol.2, 393 (2003).
- Sawle GV. Pattern of dopaminergic loss in the striatum of humans with parkinsonism induced by MPTP. J. Neurol. Neurosurg. Psychiatry68, 276 (2000).
- Snow BJ, Vingerhoets FJ, Langston JW, Tetrud JW, Sossi V, Calne DB. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg. Psychiatry68, 313–316 (2000).
- Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson’s disease and parkinsonism. Ann. Neurol.60, 389–398 (2006).
- Funayama M, Hasegawa K, Ohta E et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol.57, 918–921 (2005).
- Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol.51, 296–301 (2002).
- Zimprich A, Biskup S, Leitner P et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron44, 601–607 (2004).
- Paisán-Ruíz C, Jain S, Evans EW et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron44, 595–600 (2004).
- Khan NL, Jain S, Lynch JM et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson’s disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain128, 2786–2796 (2005).
- Wszolek ZK, Vieregge P, Uitti RJ et al. German-Canadian family (family A) with Parkinsonism, amyotrophy, and dementia – longitudinal observations. Parkinsonism Relat. Disord.3, 125–139 (1997).
- Wszolek ZK, Pfeiffer RF, Tsuboi Y1 et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology62, 1619–1622 (2004).
- Gilks WP, Abou-Sleiman PM, Gandhi S et al. A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet365, 415–416 (2005).
- Di Fonzo A, Rohé CF, Ferreira J et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. Lancet365, 412–415 (2005).
- Nichols WC, Pankratz N, Hernandez D et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. Lancet365, 410–412 (2005).
- Ozelius LJ, Senthil G, Saunders-Pullman R et al. LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N. Engl. J. Med.354, 424–425 (2006).
- Lesage S, Dürr A, Tazir M et al. LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N. Engl. J. Med.354, 422–423 (2006).
- Simón-Sánchez J, Martí-Massó JF, Sánchez-Mut JV et al. Parkinson’s disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. Mov. Disord.21, 1954–1959 (2006).
- Goldwurm S, Zini M, Mariani L et al. Evaluation of LRRK2 G2019S penetrance. Neurology68(14), 1141–1143 (2007).
- Taylor JP, Mata IF, Farrer MJ. LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? Trends Mol. Med.12, 76–82 (2006).
- Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in Parkinson’s disease: protein domains and functional insights. Trends Neurosci.29, 286–293 (2006).
- Ross CA, Poirier MA. Opinion: what is the role of protein aggregation in neurodegeneration? Nat. Rev. Mol. Cell. Biol.6, 891–898 (2005).
- Scherzinger E, Sittler A, Schweiger K et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington’s disease pathology. Proc. Natl Acad. Sci. USA96, 4604–4609 (1999).
- Gloeckner CJ, Kinkl N, Schumacher A et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet.15, 223–232 (2006).
- West AB, Moore DJ, Biskup S et al. Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA102, 16842–16847 (2005).
- West AB, Moore DJ, Choi C et al. Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet.16, 223–232 (2007).
- Lotharius J, Falsig J, van Beek J et al. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J. Neurosci.25, 6329–6342 (2005).
- Golbe LI, Di Iorio G, Sanges G et al. Clinical genetic analysis of Parkinson’s disease in the Contursi kindred. Ann. Neurol.40, 767–775 (1996).
- Polymeropoulos MH, Higgins JJ, Golbe LI et al. Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science274, 1197–1199 (1996).
- Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science276, 2045–2047 (1997).
- Zarranz JJ, Alegre J, Gómez-Esteban JC et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol.55, 164–173 (2004).
- Krüger R, Kuhn W, Müller T et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease. Nat. Genet.18, 106–108 (1998).
- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. α-synuclein in Lewy bodies. Nature388, 839–840 (1997).
- Singleton AB, Farrer M, Johnson J et al. α-synuclein locus triplication causes Parkinson’s disease. Science302, 841 (2003).
- Miller DW, Hague SM, Clarimon J et al. α-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology62, 1835–1838 (2004).
- Singleton A, Myers A, Hardy J. The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases. Hum. Mol. Genet.13(Spec. No 1), R123–R126 (2004).
- Chartier-Harlin MC, Kachergus J, Roumier C et al. α-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet364, 1167–1169 (2004).
- Lee VM, Trojanowski JQ. Mechanisms of Parkinson’s disease linked to pathological α-synuclein: new targets for drug discovery. Neuron52, 33–38 (2006).
- Beyer K. Α-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. (Berl).112, 237–251 (2006).
- Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson’s disease. Ann. Rev. Neurosci.28, 57–87 (2005).
- Larsen KE, Schmitz Y, Troyer MD et al. α-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci.26, 11915–11922 (2006).
- Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA95, 6469–6473 (1998).
- Choi W, Zibaee S, Jakes R et al. Mutation E46K increases phospholipid binding and assembly into filaments of human α-synuclein. FEBS Lett.576, 363–368 (2004).
- Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA97, 571–576 (2000).
- Paleologou KE, Irvine GB, El-Agnaf OM. α-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochem. Soc. Trans.33, 1106–1110 (2005).
- McNaught KS, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson’s disease. Neurobiol. Aging27, 530–545 (2006).
- Chiba-Falek O, Touchman JW, Nussbaum RL. Functional analysis of intra-allelic variation at NACP-Rep1 in the α-synuclein gene. Hum. Genet.113, 426–431 (2003).
- Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1 repeat upstream of the α-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet.10, 3101–3109 (2001).